CRISPR/CAS9 and mitochondrial gene replacement therapy: Promising techniques and ethical considerations

Sarah Fogleman, Casey Santana, Casey Bishop, Alyssa Miller, David Capco

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Thousands of mothers are at risk of transmitting mitochondrial diseases to their offspring each year, with the most severe form of these diseases being fatal [1]. With no cure, transmission prevention is the only current hope for decreasing the disease incidence. Current methods of prevention rely on low mutant maternal mitochondrial DNA levels, while those with levels close to or above threshold (>60%) are still at a very high risk of transmission [2]. Two novel approaches may offer hope for preventing and treating mitochondrial disease: mitochondrial replacement therapy, and CRISPR/Cas9. Mitochondrial replacement therapy has emerged as a promising tool that has the potential to prevent transmission in patients with higher mutant mitochondrial loads. This method is the subject of many ethical concerns due its use of a donor embryo to transplant the patient’s nuclear DNA; however, it has ultimately been approved for use in the United Kingdom and was recently declared ethically permissible by the FDA. The leading-edge CRISPR/Cas9 technology exploits the principles of bacterial immune function to target and remove specific sequences of mutated DNA. This may have potential in treating individuals with disease caused by mutant mitochondrial DNA. As the technology progresses, it is important that the ethical considerations herein emerge and become more established. The purpose of this review is to discuss current research surrounding the procedure and efficacy of the techniques, compare the ethical concerns of each approach, and look into the future of mitochondrial gene replacement therapy.

Original languageEnglish (US)
Pages (from-to)39-52
Number of pages14
JournalAmerican Journal of Stem Cells
Volume5
Issue number2
StatePublished - 2016

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Mitochondrial Genes
Genetic Therapy
Mitochondrial Diseases
Mitochondrial DNA
Hope
Mothers
Technology
Embryonic Structures
Tissue Donors
Transplants
DNA
Incidence
Research
Mitochondrial Replacement Therapy

Keywords

  • Assisted human reproduction
  • CRISPR-Cas systems
  • Ethics
  • Gene editing
  • Mitochondrial diseases
  • Mitochondrial replacement therapy
  • Nuclear transfer

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this

CRISPR/CAS9 and mitochondrial gene replacement therapy : Promising techniques and ethical considerations. / Fogleman, Sarah; Santana, Casey; Bishop, Casey; Miller, Alyssa; Capco, David.

In: American Journal of Stem Cells, Vol. 5, No. 2, 2016, p. 39-52.

Research output: Contribution to journalReview article

Fogleman, Sarah ; Santana, Casey ; Bishop, Casey ; Miller, Alyssa ; Capco, David. / CRISPR/CAS9 and mitochondrial gene replacement therapy : Promising techniques and ethical considerations. In: American Journal of Stem Cells. 2016 ; Vol. 5, No. 2. pp. 39-52.
@article{e75587a1e912463787da13d27a55cc32,
title = "CRISPR/CAS9 and mitochondrial gene replacement therapy: Promising techniques and ethical considerations",
abstract = "Thousands of mothers are at risk of transmitting mitochondrial diseases to their offspring each year, with the most severe form of these diseases being fatal [1]. With no cure, transmission prevention is the only current hope for decreasing the disease incidence. Current methods of prevention rely on low mutant maternal mitochondrial DNA levels, while those with levels close to or above threshold (>60{\%}) are still at a very high risk of transmission [2]. Two novel approaches may offer hope for preventing and treating mitochondrial disease: mitochondrial replacement therapy, and CRISPR/Cas9. Mitochondrial replacement therapy has emerged as a promising tool that has the potential to prevent transmission in patients with higher mutant mitochondrial loads. This method is the subject of many ethical concerns due its use of a donor embryo to transplant the patient’s nuclear DNA; however, it has ultimately been approved for use in the United Kingdom and was recently declared ethically permissible by the FDA. The leading-edge CRISPR/Cas9 technology exploits the principles of bacterial immune function to target and remove specific sequences of mutated DNA. This may have potential in treating individuals with disease caused by mutant mitochondrial DNA. As the technology progresses, it is important that the ethical considerations herein emerge and become more established. The purpose of this review is to discuss current research surrounding the procedure and efficacy of the techniques, compare the ethical concerns of each approach, and look into the future of mitochondrial gene replacement therapy.",
keywords = "Assisted human reproduction, CRISPR-Cas systems, Ethics, Gene editing, Mitochondrial diseases, Mitochondrial replacement therapy, Nuclear transfer",
author = "Sarah Fogleman and Casey Santana and Casey Bishop and Alyssa Miller and David Capco",
year = "2016",
language = "English (US)",
volume = "5",
pages = "39--52",
journal = "American Journal of Stem Cells",
issn = "2160-4150",
publisher = "e-Century Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - CRISPR/CAS9 and mitochondrial gene replacement therapy

T2 - Promising techniques and ethical considerations

AU - Fogleman, Sarah

AU - Santana, Casey

AU - Bishop, Casey

AU - Miller, Alyssa

AU - Capco, David

PY - 2016

Y1 - 2016

N2 - Thousands of mothers are at risk of transmitting mitochondrial diseases to their offspring each year, with the most severe form of these diseases being fatal [1]. With no cure, transmission prevention is the only current hope for decreasing the disease incidence. Current methods of prevention rely on low mutant maternal mitochondrial DNA levels, while those with levels close to or above threshold (>60%) are still at a very high risk of transmission [2]. Two novel approaches may offer hope for preventing and treating mitochondrial disease: mitochondrial replacement therapy, and CRISPR/Cas9. Mitochondrial replacement therapy has emerged as a promising tool that has the potential to prevent transmission in patients with higher mutant mitochondrial loads. This method is the subject of many ethical concerns due its use of a donor embryo to transplant the patient’s nuclear DNA; however, it has ultimately been approved for use in the United Kingdom and was recently declared ethically permissible by the FDA. The leading-edge CRISPR/Cas9 technology exploits the principles of bacterial immune function to target and remove specific sequences of mutated DNA. This may have potential in treating individuals with disease caused by mutant mitochondrial DNA. As the technology progresses, it is important that the ethical considerations herein emerge and become more established. The purpose of this review is to discuss current research surrounding the procedure and efficacy of the techniques, compare the ethical concerns of each approach, and look into the future of mitochondrial gene replacement therapy.

AB - Thousands of mothers are at risk of transmitting mitochondrial diseases to their offspring each year, with the most severe form of these diseases being fatal [1]. With no cure, transmission prevention is the only current hope for decreasing the disease incidence. Current methods of prevention rely on low mutant maternal mitochondrial DNA levels, while those with levels close to or above threshold (>60%) are still at a very high risk of transmission [2]. Two novel approaches may offer hope for preventing and treating mitochondrial disease: mitochondrial replacement therapy, and CRISPR/Cas9. Mitochondrial replacement therapy has emerged as a promising tool that has the potential to prevent transmission in patients with higher mutant mitochondrial loads. This method is the subject of many ethical concerns due its use of a donor embryo to transplant the patient’s nuclear DNA; however, it has ultimately been approved for use in the United Kingdom and was recently declared ethically permissible by the FDA. The leading-edge CRISPR/Cas9 technology exploits the principles of bacterial immune function to target and remove specific sequences of mutated DNA. This may have potential in treating individuals with disease caused by mutant mitochondrial DNA. As the technology progresses, it is important that the ethical considerations herein emerge and become more established. The purpose of this review is to discuss current research surrounding the procedure and efficacy of the techniques, compare the ethical concerns of each approach, and look into the future of mitochondrial gene replacement therapy.

KW - Assisted human reproduction

KW - CRISPR-Cas systems

KW - Ethics

KW - Gene editing

KW - Mitochondrial diseases

KW - Mitochondrial replacement therapy

KW - Nuclear transfer

UR - http://www.scopus.com/inward/record.url?scp=85015139831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015139831&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85015139831

VL - 5

SP - 39

EP - 52

JO - American Journal of Stem Cells

JF - American Journal of Stem Cells

SN - 2160-4150

IS - 2

ER -